Breaks Categories: Stock Spotlights

FridayOct 22, 2021 12:16 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is combined with protein-based biomarker tests to obtain even more comprehensive information, can be used to obtain more comprehensive data and information,” explains a recent article. “Unlike most liquid-based cancer screening and detection methods, the CDA platform from AnPac Bio focuses on assessing the existing protein-based…

Continue Reading

FridayOct 22, 2021 12:02 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Well Qualified to Provide Global Insight into Medical Cannabis

RYAH Group (CSE: RYAH), a connected device and big data and technology company, in a recent blog post provided insight into the cannabis medical space in Brazil, the largest South American country both in size and population, boasting a GDP per capita of $15,388. A recent article that contains excerpts from the post notes that medical cannabis in Brazil may face some steep political hurdles but that the waves of reform are slowly making it possible for more patients to access more medicine. “While the country has faced challenges, RYAH notes that Brazil seems poised at the top of a…

Continue Reading

FridayOct 15, 2021 11:37 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Focusing on What It Does Best

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently released its financial results for the twelve months ended May 31, reporting on its first full year of operations since incorporation in March 2020. “The company initially began the year developing a nootropic line of functional mushrooms and supplements, in line with the rising consumer use of cognitive enhancement nootropics to improve brain function. With the company’s renewed focus on its digital technology and research development activities, MINDCURE announced in August that it had discontinued the development of its nootropics line of…

Continue Reading

FridayOct 15, 2021 11:28 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Enabling Hospitals with Efficient EEG Testing Solution

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is making it possible for all hospitals to perform EEG tests efficiently. Its neurotech ecosystem gives neurologists the resources they need to automate tedious tasks and focus their energy on the patient while simultaneously broadening their range of impact. With the unavailability of EEGs in emergency response vehicles and a majority of the hospitals in the U.S. (around 5,900 of the approximately 6,090 total hospitals lack the necessary extensive EEG tech coverage), BRSF has created a solution that includes the clinical-grade NeuroCap(TM) and the NeuroEEG(TM). “By…

Continue Reading

FridayOct 15, 2021 11:07 am

BioMedNewsBreaks – Why Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Founded in 2011, the company set out to create a single platform technology to measure blood markers at the surface of the skin. Since then, it has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and wellbeing. “Its flagship product, sugarBEAT(R), is a wearable, non-invasive, and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and pre-diabetes manage their glucose levels. Insulin users…

Continue Reading

MondayOct 11, 2021 2:22 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Providing Reliable, Consistent Dose Administration and Monitoring Devices

RYAH Group (CSE: RYAH), a connected device and big data and technology company, offers a suite of precision intake control and management devices that provide a practical way to execute volume control guidelines safely. In a company blog post, discussed in a recent article, RYAH noted that a global task force had created three separate dosing protocols: routine administration, conservative administration and rapid administration, with each designed to ease a patient treating chronic pain into medical cannabis and treatment with THC if needed. Such dosing guidelines are just half of the equation. The other half is the delivery mechanism, as…

Continue Reading

MondayOct 11, 2021 1:42 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical property and has achieved significant results,” reads a recent article. AnPac Bio has one of the largest sample libraries in the world, with more than 220,000 samples…

Continue Reading

MondayOct 11, 2021 1:27 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain…

Continue Reading

FridayOct 08, 2021 11:36 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM) recently announced it had signed a definitive agreement to acquire 100% of BayMedica Inc., a U.S.-based private company specializing in the manufacture and commercialization of rare cannabinoids. InMed CEO Eric A. Adams described the acquisition as a transformative transaction for the company as it would give InMed a breadth of synthetic cannabinoid manufacturing capabilities. “BayMedica brings unparalleled cannabinoid manufacturing expertise in both chemical synthesis and biosynthesis together with industry veterans who have been pioneers in this space,” a recent article quotes Adams as saying. The article further notes that, once closed, the transaction will create a…

Continue Reading

MondayOct 04, 2021 10:04 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Achieves Several Key Milestones in 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, has so far reached several key milestones in 2021. According to a recent article, these include: “raising $23 million in a bought deal short form prospectus public offering that closed in February this year. On the technology side, MCURF launched the minimum viable product (‘MVP’) of iSTRYM in Q3 2021. On the drug development and research side, the company synthesized ibogaine and has launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. The company has also filed…

Continue Reading